Newsbenzinga
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
· Published
Article summary
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
An excerpt from the original article.
Comments —
Loading comments…